Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients

<table>sCEACAM1 in WED patients increases over time and as compared with NED patients. sCEACAM1 was measured by ELISA in serum samples of 29 NED (A, B) and 20 WED (C, D) malignant melanoma patients, both before (time point 0) and following treatment (time point 1). Vertical lines indicate medians.</table>

Journal of Immunology Research

fig1

Figure 1

Figure 1: Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients 